Raman spectroscopy, a potential tool in diagnosis and prognosis of castration-resistant prostate cancer
暂无分享,去创建一个
Jun Wang | Jin Zeng | Lei Wang | Peilong Cao | Liqing Huang | Xinyang Wang | Dalin He | Zhenfeng Guan | Qiang Dang | Guanjun Zhang | JerTong Hsieh | Jinhai Fan | Xin-yang Wang | D. He | J. Hsieh | Zhenfeng guan | Jinhai Fan | Lei Wang | Peilong Cao | Liqing Huang | Guanjun Zhang | J. Zeng | Q. Dang | Jun Wang
[1] Christiaan F P van Swol,et al. In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. , 2010, Analytical chemistry.
[2] Ganesh D. Sockalingum,et al. Raman spectral imaging of single cancer cells: probing the impact of sample fixation methods , 2010, Analytical and bioanalytical chemistry.
[3] K. Maquelin,et al. Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy. , 2006, Analytical chemistry.
[4] Rohit Bhargava,et al. Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging. , 2010, The Analyst.
[5] Rohit Bhargava,et al. Towards a practical Fourier transform infrared chemical imaging protocol for cancer histopathology , 2007, Analytical and bioanalytical chemistry.
[6] John Maier,et al. Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens. , 2011, European urology.
[7] C. Roehrborn,et al. Gleason score predicts androgen independent progression after androgen deprivation therapy. , 2002, European urology.
[8] Mads S. Bergholt,et al. In vivo diagnosis of gastric cancer using Raman endoscopy and ant colony optimization techniques , 2011, International journal of cancer.
[9] Lotfi Senhadji,et al. Raman spectroscopy: a novel experimental approach to evaluating renal tumours. , 2010, European urology.
[10] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[11] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates , 2010, Cancer.
[12] M W Kattan,et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] H. Byrne,et al. Vibrational spectroscopy for cervical cancer pathology, from biochemical analysis to diagnostic tool. , 2007, Experimental and molecular pathology.
[14] N. Stone,et al. The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro , 2004, BJU international.
[15] L. Chung,et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.
[16] Jin Tae Kwak,et al. Multimodal microscopy for automated histologic analysis of prostate cancer , 2011, BMC Cancer.
[17] Daniel J. Culkin,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, New England Journal of Medicine.
[18] C. Croce,et al. Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.
[19] Joe M. Byrne,et al. Raman Spectroscopic Evaluation of Efficacy of Current Paraffin Wax Section Dewaxing Agents , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[20] L. Chung,et al. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. , 2011, Cancer research.
[21] L. Egevad,et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.
[22] Alex Henderson,et al. Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy. , 2007, The Analyst.
[23] S. Hewitt,et al. Infrared spectroscopic imaging for histopathologic recognition , 2005, Nature Biotechnology.
[24] Judith D Goldberg,et al. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. , 2011, European urology.
[25] Ming-Tsang Wu,et al. Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy , 2011, The Prostate.
[26] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[27] N Stone,et al. The use of Raman spectroscopy to identify and grade prostatic adenocarcinoma in vitro , 2003, British Journal of Cancer.
[28] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[29] N Stone,et al. The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines , 2005, British Journal of Cancer.
[30] Sang Eun Lee,et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. , 2002, The Journal of urology.
[31] Francis L Martin,et al. Distinguishing cell types or populations based on the computational analysis of their infrared spectra , 2010, Nature Protocols.
[32] 上杉 達也,et al. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer , 2011 .
[33] R. Sylvester,et al. Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 , 1998, European Urology.
[34] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[35] Athanase Billis,et al. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. , 2008, The Journal of urology.
[36] R L Vessella,et al. Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .
[37] Ehsan Gazi,et al. A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage. , 2006, European urology.